The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
Kategori: Uncategorized
MDS-ES and EHDN Joint Online Course Series
The MDS-ES and EHDN Joint Online Course Series: Huntington’s Disease: From Foundational Principles to Assessment and Treatment is available for free on-demand access through the MDS Education Roadmap. […]
Photo Exhibition at the EHDN Plenary Meeting
Participate in the Photo Exhibition at the EHDN Plenary Meeting! – In collaboration with the EHA, there will be a photo exhibition organized at the EHDN2022 Plenary Meeting in September […]
European Huntington Association (EHA) – online survey
’On behalf of the EHA, please complete the survey to collect information on access to care for HD families.’ […]
HD Human Biology Project
The Huntington’s Disease Society of America has adopted a patient-centric research strategy to push the field closer to meeting our goal of identifying effective therapies. The HD Human Biology Project is the cornerstone of this strategy. … […]
17th Annual Huntington’s Disease Therapeutics Conference
CHDI’s 17th Annual HD Therapeutics Conference was back in-person after a year-long hiatus, and took place February 28 – March 3, 2022. This unique conference series focuses on drug discovery and development for Huntington’s disease, and draws participants from the biotech and pharmaceutical sectors as well as academia. The conference is intended as a forum […]
DOMINO-HD study endorsed* by EHDN
Study aims and goal: Observational study funded by JPND (EU Joint Programme – Neurodegenerative Disease Research) assessing sleep, physical activity and nutrition in people with early-to-mid stage HD using digital technology e.g. wearable fitness trackers. No. of study participants and sites: approx. 300 participants for 12 months at 5 sites in Europe (UK, Germany, Spain, […]
PROOF-HD study endorsed* by EHDN
Study aims and goal: An interventional, Phase III clinical trial to evaluate the efficacy and safety of pridopidine in patients with early stage manifest Huntington’s Disease (HD). No. of study participants and sites: The study aims to recruit 480 participants at sites in: Austria, Canada, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain, UK, USA […]
VIBRANT-HD study endorsed* by EHDN
Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD. No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, […]
Deep Brain Stimulation in HD
In December of this year, the last patient recruited into the European multi-centre deep brain stimulation study (HD-DBS) will reach the secondary endpoint (6 month follow-up). Recruitment was finished in 05/21. Perseverance pays off! The DBS team led by Professor Jan Vesper in Düsseldorf, Germany, expects data from the study to be available in 2022. […]